The KDIGO CKD 2024 Guideline Draft
It’s time for another NephJC draft! This time, the crew breaks down the 2024 KDIGO chronic kidney disease (CKD) guideline. This was the first update since 2012.
Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy
Apitegromab Improved Motor Function in Type 2/3 Spinal Muscular Atrophy
Losmapimod Did Not Benefit Patients with Facioscapulohumeral Muscular Dystrophy